Protocol 250-12951-201 is a planned Phase 2 study entitled A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of VDMN-21 in Subjects with Verruca Vulgaris. Eligible subjects will be randomized into one of the three treatment groups (high dose, low dose, vehicle).
This Phase 2 study has been designed to determine the safety and efficacy of repeated treatment sessions of VDMN-21 patch at two dose strengths as compared to a matched vehicle control patch in subjects with verruca vulgaris